Through its collaboration with Alpha Imaging Technologies, Major Health Partners (MHP) has purchased and installed Gamma Medica Inc.’s LumaGEM Molecular Breast Imaging (MBI) system, Indiana’s first LumaGEM and the hospital’s first MBI. LumaGEM MBI System installed at MHP Medical Center. Courtesy of MHP. The MBI technology will be offered as a secondary screening and diagnostic tool following mammography, particularly for women with dense breast tissue. This proven imaging modality will enhance early breast cancer detection for women who face a greater risk of breast cancer. “MHP Medical Center’s installation of our LumaGEM MBI system validates progress in giving all women, regardless of their breast density, access to accurate breast cancer screenings,” said Philip Croxford, Gamma Medica president and CEO. “Our relationship with MHP and Alpha Imaging has opened the door for more women in Indiana and the Midwest to access MBI as a standard secondary screening protocol, following digital mammography or tomosynthesis. We are pleased to be working together to ensure early detection for women across the U.S.” Designed for dense breast tissue, MBI is a groundbreaking technology that significantly improves early detection of breast cancer in women with such tissue. The technology has proven to be as effective, or more, as a secondary screening method compared to full-field ultrasound or MRI with far fewer false positives. Clinical research shows use of LumaGEM MBI reduces the need for tissue biopsies by 50 percent compared to other modalities. MBI is also more comfortable and better tolerated by most patients than conventional mammography or MRI. Gamma Medica is a developer of molecular breast imaging technology.